HBV genotype is associated with early (week 12) virologic response during TDF or TAF therapy in patients with chronic hepatitis B.

MLA

Pan C.Q., et al. HBV Genotype Is Associated with Early (Week 12) Virologic Response during TDF or TAF Therapy in Patients with Chronic Hepatitis B. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305134698&authtype=sso&custid=ns315887.

APA

Pan C.Q., Gaggar A., Myers R.P., Osipenko M., Pianko S., Chow W.-C., Acharya S.K., Lee K.S., Kao J.-H., Flisiak R., Flaherty J.F., Kim K., & Lin L. (2016). HBV genotype is associated with early (week 12) virologic response during TDF or TAF therapy in patients with chronic hepatitis B.

Chicago

Pan C.Q., Gaggar A., Myers R.P., Osipenko M., Pianko S., Chow W.-C., Acharya S.K., et al. 2016. “HBV Genotype Is Associated with Early (Week 12) Virologic Response during TDF or TAF Therapy in Patients with Chronic Hepatitis B.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305134698&authtype=sso&custid=ns315887.